Molecular targeting therapy for renal cell carcinoma

Masatoshi Eto, Seiji Naito

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Metastatic renal cell carcinoma (RCC) is currently one of the most treatment-resistant malignancies. However, significant advances in understanding the molecular mechanisms underlying RCC have led to the development of rationally designed therapies, which are now being tested clinically. To date, the vascular endothelial growth factor receptor (VEGFR) pathway has been the most promising target, and two agents (BAY 43-9006 and SU 11248) that inhibit not only VEGFR but also other receptors, including platelet-derived growth factor receptor (PDGFR), FMS-like tyrosine kinase 3 (FLT3), KIT, and Raf kinase, were recently approved by the FDA for advanced RCC. In addition, a phase III trial investigating the addition of VEGF inhibition to interferon alpha (IFN-α) in RCC is also now going on. Although the clinical activity of existing agents is to be further defined in ongoing trials, the exciting clinical response data with VEGF inhibition in RCC have demonstrated a key role in the treatment of this historically resistant malignancy.

Original languageEnglish
Pages (from-to)209-213
Number of pages5
JournalInternational Journal of Clinical Oncology
Volume11
Issue number3
DOIs
Publication statusPublished - Jun 1 2006

Fingerprint

Renal Cell Carcinoma
Vascular Endothelial Growth Factor Receptor
Vascular Endothelial Growth Factor A
raf Kinases
Therapeutics
Platelet-Derived Growth Factor Receptors
Interferon-alpha
Protein-Tyrosine Kinases
Neoplasms
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

Cite this

Molecular targeting therapy for renal cell carcinoma. / Eto, Masatoshi; Naito, Seiji.

In: International Journal of Clinical Oncology, Vol. 11, No. 3, 01.06.2006, p. 209-213.

Research output: Contribution to journalReview article

@article{2a68d2f2c029404394a4c6053148023c,
title = "Molecular targeting therapy for renal cell carcinoma",
abstract = "Metastatic renal cell carcinoma (RCC) is currently one of the most treatment-resistant malignancies. However, significant advances in understanding the molecular mechanisms underlying RCC have led to the development of rationally designed therapies, which are now being tested clinically. To date, the vascular endothelial growth factor receptor (VEGFR) pathway has been the most promising target, and two agents (BAY 43-9006 and SU 11248) that inhibit not only VEGFR but also other receptors, including platelet-derived growth factor receptor (PDGFR), FMS-like tyrosine kinase 3 (FLT3), KIT, and Raf kinase, were recently approved by the FDA for advanced RCC. In addition, a phase III trial investigating the addition of VEGF inhibition to interferon alpha (IFN-α) in RCC is also now going on. Although the clinical activity of existing agents is to be further defined in ongoing trials, the exciting clinical response data with VEGF inhibition in RCC have demonstrated a key role in the treatment of this historically resistant malignancy.",
author = "Masatoshi Eto and Seiji Naito",
year = "2006",
month = "6",
day = "1",
doi = "10.1007/s10147-006-0577-2",
language = "English",
volume = "11",
pages = "209--213",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Molecular targeting therapy for renal cell carcinoma

AU - Eto, Masatoshi

AU - Naito, Seiji

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Metastatic renal cell carcinoma (RCC) is currently one of the most treatment-resistant malignancies. However, significant advances in understanding the molecular mechanisms underlying RCC have led to the development of rationally designed therapies, which are now being tested clinically. To date, the vascular endothelial growth factor receptor (VEGFR) pathway has been the most promising target, and two agents (BAY 43-9006 and SU 11248) that inhibit not only VEGFR but also other receptors, including platelet-derived growth factor receptor (PDGFR), FMS-like tyrosine kinase 3 (FLT3), KIT, and Raf kinase, were recently approved by the FDA for advanced RCC. In addition, a phase III trial investigating the addition of VEGF inhibition to interferon alpha (IFN-α) in RCC is also now going on. Although the clinical activity of existing agents is to be further defined in ongoing trials, the exciting clinical response data with VEGF inhibition in RCC have demonstrated a key role in the treatment of this historically resistant malignancy.

AB - Metastatic renal cell carcinoma (RCC) is currently one of the most treatment-resistant malignancies. However, significant advances in understanding the molecular mechanisms underlying RCC have led to the development of rationally designed therapies, which are now being tested clinically. To date, the vascular endothelial growth factor receptor (VEGFR) pathway has been the most promising target, and two agents (BAY 43-9006 and SU 11248) that inhibit not only VEGFR but also other receptors, including platelet-derived growth factor receptor (PDGFR), FMS-like tyrosine kinase 3 (FLT3), KIT, and Raf kinase, were recently approved by the FDA for advanced RCC. In addition, a phase III trial investigating the addition of VEGF inhibition to interferon alpha (IFN-α) in RCC is also now going on. Although the clinical activity of existing agents is to be further defined in ongoing trials, the exciting clinical response data with VEGF inhibition in RCC have demonstrated a key role in the treatment of this historically resistant malignancy.

UR - http://www.scopus.com/inward/record.url?scp=33746127995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746127995&partnerID=8YFLogxK

U2 - 10.1007/s10147-006-0577-2

DO - 10.1007/s10147-006-0577-2

M3 - Review article

C2 - 16850127

AN - SCOPUS:33746127995

VL - 11

SP - 209

EP - 213

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 3

ER -